Messages from Top Management

Growth is Driven by Collaborative Innovation.
Value is Borne of Complementary Strengths.

At CosMED Pharmaceutical, through technological development based on transdermal therapeutic system (TTS) research, we support research and product development at businesses, universities, and medical institutions. Our growth is driven by collaborative innovation with partners who face a variety of challenges in a range of fields. These new encounters give rise to innovative ideas and original results.

CosMED Pharmaceutical itself was borne from my association with Ying-shu Quan (current President and Representative Director), who was specializing in a field different from my own. The technology that supports growth at CosMED Pharmaceutical today was created by combining Ying-shu Quan’s expertise in pharmacology and dermatological mechanisms and my work in polymer technology.

One of these technologies created by CosMED Pharmaceutical is the world’s first* industrial process for the manufacture of dissolving microneedles, established in 2008. At the time, I was studying polymer-based microneedles when Ying-shu Quan proposed the idea of developing needles made from hyaluronic acid for cosmetics applications. Mutual respect for our respective fields of expertise and our combined support and motivation bore fruit in microneedle cosmetics.

To this day, we remain committed to pursuing research and making even greater advances in microneedle technology. Two recent successes have been needles made out of triple-helical collagen and the development of taurine crystal microneedles. Our technology is also being adapted for next-generation continuous blood glucose monitoring devices and we are involved in developing self-administered vaccines that can be applied safely by the individual.

Our desire to “improve society through innovative ideas and proven technology” remains as strong as it was when CosMED was founded. We are committed to inspiring collaborative innovation and our enduring goal as a company is unparalleled innovation and quality through technology.

Chairperson, Doctor of Engineering
Fumio Kamiyama

Creating a Happier Future through the Innovative Concept of Friendly Medical Care

CosMED Pharmaceutical began its journey with the aspiration to develop unique products that improve people’s everyday lives. Since founding the company, we have maintained a unique focus on transdermal therapeutic systems (TTSs) that deliver drugs through the skin and developed a unique expertise in this field.

Dissolving microneedles are used in adhesive needle patches that deliver drugs to the user without pain or injury, and CosMED Pharmaceutical was the first in the world* to develop a usable example of this technology. At one point, microneedles were only made from metal or glass. Seeking a safer method of drug delivery via microneedles, we pursued the original idea of creating the needles from the same material that makes up the skin and developed dissolving microneedles as a result. Dissolving microneedles, which allow cosmetic agents to reach the stratum corneum, were then adapted for cosmetics applications and have become a revolutionary technology in the beauty industry. This work created the microneedle cosmetics market.

As a venture-oriented enterprise, we are passionate about creating new products and recognize the value of pursuing research. CosMED is committed to finding solutions that offer friendlier methods of drug delivery and create a society where the benefits of medical care are more accessible to everyone.

We believe CosMED Pharmaceutical has been successful in creating innovative products and services thanks to its continued pursuit of a future rich with “friendly medical care” that caters to the individual.

Our next dream is vaccine microneedle array patches that allow vaccines previously only available by injection to be self-administered by the user. Microneedle array patches can greatly reduce workloads for healthcare professionals and create a world better able to deal with infectious disease pandemics.

As specialists in transdermal therapeutic systems (TTSs), CosMED Pharmaceutical is committed to developing the next generation of microneedle technology for the medical and pharmaceutical sectors.

President and Representative Director, Doctor of Pharmacology
Ying-shu Quan

*From the Journal of Pharmaceutical Science and Technology, Japan, published by The Academy of Pharmaceutical Science and Technology, Japan